The CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024 provides updated recommendations based on recent advances. It emphasizes procedural aspects of PCI, including intravascular imaging, timing of revascularization, and antiplatelet therapy for high-bleeding risk patients.
The EAACI Biologicals Guidelines for the treatment of chronic spontaneous urticaria (CSU) with omalizumab provide a comprehensive approach to managing this condition. The guidelines address practical issues such as responder selection, treatment duration, and cost-effectiveness.
Read the transcript of an expert presentation on the complexity of HS pathophysiology, presented at EADV 2024 by Dr Hessel van der Zee.
Read the transcript of an expert presentation on the pain assessment tools available for people with HS, presented at EADV 2024 by Bart Morlion.
Recent publications will be reviewed and distilled into key learning points for your convenience, sorted by year of publication.
Read the latest publication digest "Anticoagulation reversal for intracranial haemorrhage in the era of the direct oral anticoagulants".
Read the latest publication digest "A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus?".
Review our recent article 'Reversal of warfarin-associated major haemorrhage: activated prothrombin complex concentrate versus 4-factor prothrombin complex concentrate.
Discover thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: a comparison between 3-factor PCC 4-factor PCC.
Discover in this study the efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban.